Extract

The primary objective of this study is to evaluate the effects of aflibercept on the QTc interval in cancer patients. Secondary objectives are to evaluate the effects of aflibercept on other electrocardiogram (ECG) parameters, clinical safety and pharmakokinetic (PK) parameters.

Inclusion criteria

• Cancer

Country

• Belgium
• Denmark
• Germany
• Italy
• Romania
• Turkey
• United States

Links

• ictrp
• nct